Search results for "Theria"

showing 4 items of 94 documents

Combination vaccines containing DTPa–Hib: impact of IPV and coadministration of CRM197 conjugates

2008

Vaccination with diphtheria-tetanus-acellular pertussis (DTPa)-Haemophilus influenzae type b (Hib) combinations generally elicits anti-polyribosyl-ribitol-phosphate (PRP) antibody concentrations of more than 0.15 microg/ml, a criterion that is linked to the protection of infants against Hib disease. In the UK, vaccination with DTPa3-Hib elicited atypically low anti-PRP antibody levels and was associated with breakthrough Hib cases. While the absence of a toddler booster is considered to be a key factor explaining the lowered control of Hib disease, we propose that the coadministration of serogroup C Neisseria meningitidis conjugate vaccine (MenC)-CRM197, which coincided with the introductio…

health care facilities manpower and servicesImmunologyDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causecomplex mixturesBacterial ProteinsAntigenConjugate vaccineImmunityDrug DiscoveryHumansMedicineDiphtheria-Tetanus-acellular Pertussis VaccinesHaemophilus VaccinesPharmacologybusiness.industryNeisseria meningitidisToxoidHepatitis Bbacterial infections and mycosesmedicine.diseaseVirologyUnited Kingdomcarbohydrates (lipids)VaccinationPoliovirus Vaccine InactivatedImmunologybacteriaMolecular MedicinebusinessExpert Review of Vaccines
researchProduct

The seroepidemiology of pertussis in Australia during an epidemic period

2006

Studying the epidemiology of pertussis and impact of differing vaccine schedules is difficult because of differing methods of case ascertainment. The advent of internationally standardized serological diagnosis for recent infection has allowed comparison of age-specific pertussis infection among European countries and was applied in Australia at the time of a major national epidemic. In 1997 and 1998, a nationally representative serum bank using residual sera from diagnostic laboratories was established. Measurement of pertussis toxin (PT) IgG level was conducted by a reference laboratory using an enzyme-linked immunosorbent assay standardized for a number of European countries. A titre of …

medicine.medical_specialtyAdolescentWhooping CoughEpidemiologyVaccination scheduleReference laboratoryPertussis toxinBordetella pertussisSerologySeroepidemiologic StudiesEpidemiologymedicineHumansChildAustralia/epidemiology Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage AdolescentDiphtheria-Tetanus-Pertussis VaccineWhooping coughTransmission (medicine)business.industryAustraliaInfantmedicine.diseaseVaccinationInfectious DiseasesChild PreschoolPopulation SurveillanceImmunologybusinessResearch ArticleDemographyEpidemiology and Infection
researchProduct

Agouti-related peptide-expressing neurons are mandatory for feeding.

2005

Multiple hormones controlling energy homeostasis regulate the expression of neuropeptide Y (NPY) and agouti-related peptide (AgRP) in the arcuate nucleus of the hypothalamus. Nevertheless, inactivation of the genes encoding NPY and/or AgRP has no impact on food intake in mice. Here we demonstrate that induced selective ablation of AgRP-expressing neurons in adult mice results in acute reduction of feeding, demonstrating direct evidence for a critical role of these neurons in the regulation of energy homeostasis.

medicine.medical_specialtyPro-OpiomelanocortinTime FactorsPeptideCell CountBiologyEnergy homeostasisEatingMiceArcuate nucleusInternal medicinemedicineAnimalsAgouti-Related ProteinDiphtheria ToxinNeuropeptide YRegulation of gene expressionchemistry.chemical_classificationMice KnockoutNeuronsGeneral Neurosciencedigestive oral and skin physiologyBody WeightArcuate Nucleus of HypothalamusProteinsFeeding BehaviorNeuropeptide Y receptorbeta-GalactosidaseAnorexiaEndocrinologynervous systemchemistryGene Expression RegulationHypothalamusIntercellular Signaling Peptides and ProteinsAgouti-related peptidehormones hormone substitutes and hormone antagonistsHormoneNature neuroscience
researchProduct

Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b vaccine; Infanrix™ hexa: T…

2014

Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11–12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been a…

safetybooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Clinical Trials as Topic; Diphtheria-Tetanus-Pertussis Vaccine; Haemophilus Vaccines; Hepatitis B Vaccines; Humans; Italy; Poliovirus Vaccine Inactivated; Product Surveillance Postmarketing; Vaccination; Vaccines Combined; Medicine (all)Settore MED/42 - Igiene Generale e ApplicataImmunologySocio-culturaleReviewimmunogenicitySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeprimary vaccinationProduct Surveillance PostmarketingmedicineImmunology and AllergyHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPharmacologycombination vaccinesbooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Medicine (all)Clinical Trials as TopicVaccinescombination vaccineTetanusbusiness.industryCombinedImmunogenicityPoliovirusDiphtheriaMedicine (all)VaccinationInactivatedHepatitis Bmedicine.diseaseVirologyProduct SurveillancePostmarketingClinical trialVaccinationPoliovirus Vaccinebooster vaccinationPoliovirus Vaccine InactivatedInfanrix hexaItalyhexavalent vaccine; primary vaccination; booster vaccination; Italy; combination vaccines; immunogenicity; safetybusinesshexavalent vaccine
researchProduct